Animal Models for FXTAS

  • Rob Willemsen
  • Yujing Li
  • Robert F. Berman
  • Judith R. Brouwer
  • Ben A. Oostra
  • Peng Jin


The use of model organisms is essential in order to understand the pathogenesis of many types of human disease, and this is particularly true for the study of genetic diseases such as fragile X syndrome and fragile X-associated tremor/ataxia syndrome (FXTAS). In reverse genetics, the functional study of a gene starts with the question of how a possible phenotype may derive from a specific genetic sequence (disease-causing mutation in a gene). As a first step, a gene function is purposefully altered and the effect on the normal development and/or behavior of the model organism is analyzed. In addition to providing knowledge about the cellular and molecular mechanisms underlying specific genes and their functions, animal models of human disease also provide systems for developing and validating therapeutic strategies.

The choice of which animal model is most suitable to mimic a particular disease depends on a range of factors, including anatomical, physiological, and pathological similarity; presence of orthologs of genes of interest; and conservation of basic cell biological and metabolic processes. In this chapter, we will discuss two model organisms, a mammalian vertebrate (mouse) and an invertebrate model (fly), which have been generated to study the pathogenesis of FXTAS and the effects of potential therapeutic interventions. Both mouse and fly models have proven invaluable for the study of the pathophysiology of FXTAS, including insights into the role of mutant mRNA in this disease (i.e., RNA gain-of-function mechanisms, see  Chapter 6).


Fmr1 Gene Premutation Carrier Repeat Tract Intranuclear Neuronal Inclusion Repeat Instability 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. Allen, E. G. et al. 2004. A study of the distributional characteristics of FMR1 transcript levels in 238 individuals. Hum Genet 114: 439–447.PubMedCrossRefGoogle Scholar
  2. Bacalman, S. et al. 2006. Psychiatric phenotype of the fragile X-associated tremor/ataxia syndrome (FXTAS) in males: newly described fronto-subcortical dementia. J Clin Psychiatry 67: 87–94.PubMedCrossRefGoogle Scholar
  3. Bergink, S. et al. 2006. The DNA repair-ubiquitin-associated HR23 proteins are constituents of neuronal inclusions in specific neurodegenerative disorders without hampering DNA repair. Neurobiol Dis 23: 708–716.PubMedCrossRefGoogle Scholar
  4. Bilen, J., Bonini, N. M. 2005. Drosophila as a model for human neurodegenerative disease. Annu Rev Genet 39: 153–171.PubMedCrossRefGoogle Scholar
  5. Bontekoe, C. J. M. et al. 1997. FMR1 premutation allele is stable in mice. Eur J Hum Genet 5: 293–298.PubMedGoogle Scholar
  6. Bontekoe, C. J. et al. 2001. Instability of a (CGG)(98) repeat in the Fmr1 promoter. Hum Mol Genet 10: 1693–1699.PubMedCrossRefGoogle Scholar
  7. Bourgeois, J. A. et al. 2007. Cognitive, anxiety and mood disorders in the fragile X-associated tremor/ataxia syndrome. Gen Hosp Psychiatry 29: 349–356.PubMedCrossRefGoogle Scholar
  8. Brouwer, J. R. et al. 2007. Elevated Fmr1 mRNA levels and reduced protein expression in a mouse model with an unmethylated fragile X full mutation. Exp Cell Res 313: 244–253.PubMedCrossRefGoogle Scholar
  9. Brouwer, J. R. et al. 2008a. Altered hypothalamus-pituitary-adrenal gland axis regulation in the expanded CGG-repeat mouse model for fragile X-associated tremor/ataxia syndrome. Psychoneuroendocrinology 33: 863–873.PubMedCrossRefGoogle Scholar
  10. Brouwer, J. R. et al. 2008b. CGG-repeat length and neuropathological and molecular correlates in a mouse model for fragile X-associated tremor/ataxia syndrome. J Neurochem 107: 1671–1682.PubMedCrossRefGoogle Scholar
  11. Chan, H. Y. et al. 2002. Genetic modulation of polyglutamine toxicity by protein conjugation pathways in drosophila. Hum Mol Genet 11: 2895–2904.PubMedCrossRefGoogle Scholar
  12. Chen, Y., Tassone, F., Berman, R. F., Hagerman, P. J., Hagerman, R. J., Willemsen, R., Pessah, I. N. 2010 Jan 1. Murine hippocampal neurons expressing Fmr1 gene premutations show early developmental deficits and late degeneration. Hum Mol Genet 19(1): 196–208.Google Scholar
  13. Cornish, K. M. et al. 2008. Age-dependent cognitive changes in carriers of the fragile X syndrome. Cortex 44: 628–636.PubMedCrossRefGoogle Scholar
  14. Cummings, C. J. et al. 2001. Over-expression of inducible Hsp70 chaperone suppresses neuropathology and improves motor function in SCA1 mice. Hum Mol Genet 10: 1511–1518.PubMedCrossRefGoogle Scholar
  15. de Fougerolles, A. et al. 2007. Interfering with disease: a progress report on siRNA-based therapeutics. Nat Rev Drug Discov 6: 443–453.PubMedCrossRefGoogle Scholar
  16. Entezam, A. et al. 2007. Regional FMRP deficits and large repeat expansions into the full mutation range in a new fragile X premutation mouse model. Gene 395: 125–134.PubMedCrossRefGoogle Scholar
  17. Entezam, A., Usdin, K. 2007. ATR protects the genome against CGG*CGG-repeat expansion in fragile X premutation mice. Nucleic Acids Res 36: 1050–1056.PubMedCrossRefGoogle Scholar
  18. Fernandez-Funez, P. et al. 2000. Identification of genes that modify ataxin-1-induced neurodegeneration. Nature 408: 101–106.PubMedCrossRefGoogle Scholar
  19. Greco, C. M. et al. 2002. Neuronal intranuclear inclusions in a new cerebellar tremor/ataxia syndrome among fragile X carriers. Brain 125: 1760–1771.PubMedCrossRefGoogle Scholar
  20. Greco, C. M. et al. 2006. Neuropathology of fragile X-associated tremor/ataxia syndrome (FXTAS). Brain 129: 243–255.PubMedCrossRefGoogle Scholar
  21. Greco, C. M. et al. 2007. Testicular and pituitary inclusion formation in fragile X associated tremor/ataxia syndrome. J Urol 177: 1434–1437.PubMedCrossRefGoogle Scholar
  22. Grigsby, J. et al. 2008. Cognitive profile of fragile X premutation carriers with and without fragile X-associated tremor/ataxia syndrome. Neuropsychology 22: 48–60.PubMedCrossRefGoogle Scholar
  23. Hagerman, R. J. et al. 2001. Intention tremor, parkinsonism, and generalized brain atrophy in male carriers of fragile X. Neurology 57: 127–130.PubMedCrossRefGoogle Scholar
  24. Hagerman, P. J., Hagerman, R. J. 2004. Fragile X-associated tremor/ataxia syndrome (FXTAS). Ment Retard Dev Disabil Res Rev 10: 25–30.PubMedCrossRefGoogle Scholar
  25. Handa, V. et al. 2003. The fragile X syndrome repeats form RNA hairpins that do not activate the interferon-inducible protein kinase, PKR, but are cut by dicer. Nucleic Acids Res 31: 6243–6248.PubMedCrossRefGoogle Scholar
  26. Hessl, D. et al. 2005. Abnormal elevation of FMR1 mRNA is associated with psychological symptoms in individuals with the fragile X premutation. Am J Med Genet B Neuropsychiatr Genet 139B: 115–121.PubMedCrossRefGoogle Scholar
  27. Hessl, D. et al. 2006. Amygdala dysfunction in men with the fragile X premutation. Brain 130(2): 404–416.PubMedCrossRefGoogle Scholar
  28. Hunter, J. E. et al. 2008. Investigation of phenotypes associated with mood and anxiety among male and female fragile X premutation carriers. Behav Genet 38(5): 493–502.PubMedCrossRefGoogle Scholar
  29. Iwahashi, C. et al. 2006. Protein composition of the intranuclear inclusions of FXTAS. Brain 129: 256–271.Google Scholar
  30. Iyer, R. R. et al. 2000. DNA polymerase III proofreading mutants enhance the expansion and deletion of triplet repeat sequences in Escherichia coli. J Biol Chem 275: 2174–2184.PubMedCrossRefGoogle Scholar
  31. Jacquemont, S. et al. 2004. Aging in individuals with the FMR1 mutation. Am J Ment Retard 109: 154–164.PubMedCrossRefGoogle Scholar
  32. Jakupciak, J. P., Wells, R. D. 1999. Genetic instabilities in (CTG.CAG) repeats occur by recombination. J Biol Chem 274: 23468–23479.PubMedCrossRefGoogle Scholar
  33. Jin, P. et al. 2003. RNA-mediated neurodegeneration caused by the fragile X premutation rCGG repeats in drosophila. Neuron 39: 739–747.PubMedCrossRefGoogle Scholar
  34. Jin, P. et al. 2007. Pur alpha binds to rCGG repeats and modulates repeat-mediated neurodegeneration in a drosophila model of fragile X tremor/ataxia syndrome. Neuron 55: 556–564.PubMedCrossRefGoogle Scholar
  35. Jin, P., Warren, S. T. 2003. New insights into fragile X syndrome: from molecules to neurobehaviors. Trends Biochem Sci 28: 152–158.PubMedCrossRefGoogle Scholar
  36. Kazemi-Esfarjani, P., Benzer, S. 2000. Genetic suppression of polyglutamine toxicity in drosophila. Science 287: 1837–1840.PubMedCrossRefGoogle Scholar
  37. Kenneson, A. et al. 2001. Reduced FMRP and increased FMR1 transcription is proportionally associated with CGG repeat number in intermediate-length and premutation carriers. Hum Mol Genet 10: 1449–1454.PubMedCrossRefGoogle Scholar
  38. Khalili, K. et al. 2003. Pur alpha is essential for postnatal brain development and developmentally coupled cellular proliferation as revealed by genetic inactivation in the mouse. Mol Cell Biol 23: 6857–6875.PubMedCrossRefGoogle Scholar
  39. Krol, J. et al. 2007. Ribonuclease dicer cleaves triplet repeat hairpins into shorter repeats that silence specific targets. Mol Cell 25: 575–586.PubMedCrossRefGoogle Scholar
  40. Ladd, P. D. et al. 2007. An antisense transcript spanning the CGG repeat region of FMR1 is upregulated in premutation carriers but silenced in full mutation individuals. Hum Mol Genet 16: 3174–3187.PubMedCrossRefGoogle Scholar
  41. Lavedan, C. N. et al. 1997. Trinucleotide repeats (CGG)22TGG(CGG)43TGG(CGG)21 from the fragile X gene remain stable in transgenic mice. Hum Genet 100: 407–414.PubMedCrossRefGoogle Scholar
  42. Lavedan, C. et al. 1998. Long uninterrupted CGG repeats within the first exon of the human FMR1 gene are not intrinsically unstable in transgenic mice. Genomics 50: 229–240.PubMedCrossRefGoogle Scholar
  43. Louis, E. et al. 2006. Parkinsonism, dysautonomia, and intranuclear inclusions in a fragile X carrier: a clinical-pathological study. Mov Disord 27: 193–201.Google Scholar
  44. Peier, A., Nelson, D. 2002. Instability of a premutation-sized CGG repeat in FMR1 YAC transgenic mice. Genomics 80: 423–432.PubMedCrossRefGoogle Scholar
  45. Primerano, B. et al. 2002. Reduced FMR1 mRNA translation efficiency in fragile X patients with premutations. RNA 8: 1–7.CrossRefGoogle Scholar
  46. Sofola, O. A. et al. 2007a. Argonaute-2 dependent rescue of a drosophila model of FXTAS by FRAXE premutation repeat. Hum Mol Genet 16: 2326–2332.PubMedCrossRefGoogle Scholar
  47. Sofola, O. A. et al. 2007b. RNA-binding proteins hnRNP A2/B1 and CUGBP1 suppress fragile X CGG premutation repeat-induced neurodegeneration in a drosophila model of FXTAS. Neuron 55: 565–571.PubMedCrossRefGoogle Scholar
  48. Tassone, F. et al. 2000. Elevated levels of FMR1 mRNA in carrier males: A new mechanism of involvement in the Fragile-X syndrome. Am J Hum Genet 66: 6–15.Google Scholar
  49. Tassone, F. et al. 2004. Intranuclear inclusions in neural cells with premutation alleles in fragile X associated tremor/ataxia syndrome. J Med Genet 41: E43.PubMedCrossRefGoogle Scholar
  50. Van Dam, D. et al. 2005. Cognitive decline, neuromotor and behavioural disturbances in a mouse model for Fragile-X-associated tremor/ataxia syndrome (FXTAS). Behav Brain Res 162: 233–239.PubMedCrossRefGoogle Scholar
  51. Warrick, J. M. et al. 1998. Expanded polyglutamine protein forms nuclear inclusions and causes neural degeneration in drosophila. Cell 93: 939–949.PubMedCrossRefGoogle Scholar
  52. White, P. J. et al. 1999. Stability of the human fragile X (CGG)(n) triplet repeat array in saccharomyces cerevisiae deficient in aspects of DNA metabolism. Mol Cell Biol 19: 5675–5684.PubMedGoogle Scholar
  53. Willemsen, R. et al. 2003. The FMR1 CGG repeat mouse displays ubiquitin-positive intranuclear neuronal inclusions; implications for the cerebellar tremor/ataxia syndrome. Hum Mol Genet 12: 949–959.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Rob Willemsen
    • 1
  • Yujing Li
    • 2
  • Robert F. Berman
    • 3
  • Judith R. Brouwer
    • 1
  • Ben A. Oostra
    • 1
  • Peng Jin
    • 2
  1. 1.Department of Clinical GeneticsErasmus MCRotterdamThe Netherlands
  2. 2.Department of Human GeneticsEmory University School of MedicineAtlantaUSA
  3. 3.Department of Neurological Surgery, Neurotherapeutics Research InstituteUniversity of CaliforniaDavisUSA

Personalised recommendations